ACLX Arcellx, Inc. Stock Quote

ACLX [NASD]

Index	-	P/E	-	EPS (ttm)	-3.10	Insider Own	9.20%	Shs Outstand	35.74M	Perf Week	2.20%
Market Cap	812.04M	Forward P/E	-	EPS next Y	-4.55	Insider Trans	8.67%	Shs Float	26.61M	Perf Month	48.14%
Income	-86.10M	PEG	-	EPS next Q	-1.29	Inst Own	61.40%	Short Float	2.96%	Perf Quarter	32.68%
Sales	-	P/S	-	EPS this Y	-102.40%	Inst Trans	-	Short Ratio	3.40	Perf Half Y	-
Book/sh	10.67	P/B	1.79	EPS next Y	11.00%	ROA	-	Target Price	28.67	Perf Year	-
Cash/sh	4.96	P/C	3.85	EPS next 5Y	-	ROE	-	52W Range	6.03 - 26.91	Perf YTD	13.57%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-29.10%	Beta	-
Dividend %	-	Quick Ratio	13.10	Sales past 5Y	-	Gross Margin	-	52W Low	216.16%	ATR	2.33
Employees	78	Current Ratio	13.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	61.13	Volatility	8.97% 16.90%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-496.70%	Profit Margin	-	Rel Volume	1.13	Prev Close	18.60
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	231.78K	Price	19.08
Recom	1.20	SMA20	7.11%	SMA50	46.77%	SMA200	32.33%	Volume	257,365	Change	2.58%

Mar-01-22

Initiated

SVB Leerink

Outperform

$47

Mar-01-22

Initiated

BofA Securities

Buy

$24

Jun-23-22 10:50AM	We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely Simply Wall St. +7.89%
Jun-21-22 04:05PM	Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel PR Newswire
04:01PM	Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares PR Newswire
Jun-15-22 10:47PM	Arcellx Announces Upsizing and Pricing of Follow-On Public Offering PR Newswire
Jun-10-22 05:00PM	ASCO 2022: Surprising News in Cancer Research Motley Fool +16.39%
Jun-06-22 04:09PM	How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer Investor's Business Daily +20.63%
Jun-03-22 04:00PM	Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting PR Newswire
May-27-22 09:57AM	Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting MarketWatch +20.56%
May-23-22 04:05PM	Arcellx Appoints Michelle Gilson as Chief Financial Officer PR Newswire +11.03%
May-16-22 04:01PM	Arcellx Appoints Olivia Ware to Board of Directors PR Newswire -14.59%
May-12-22 04:01PM	Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results PR Newswire
May-10-22 04:01PM	Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire +13.60%
May-09-22 04:01PM	Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma PR Newswire -7.28%
10:00AM	Here's What Arcellx, Inc.'s (NASDAQ:ACLX) Shareholder Ownership Structure Looks Like Simply Wall St.
May-05-22 04:01PM	Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference PR Newswire
Apr-27-22 10:00AM	Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
Apr-08-22 01:00PM	Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting PR Newswire
Mar-24-22 04:01PM	Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results PR Newswire
Mar-10-22 04:26PM	Arcellx Announces Participation at the Barclays Global Healthcare Conference PR Newswire
Mar-08-22 05:25PM	Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022 PR Newswire
Feb-08-22 04:01PM	Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
01:54PM	5 things to know about this cancer-focused biopharmas recent IPO American City Business Journals
Feb-04-22 05:03PM	Arcellx and Nuvectis Pharma Begin Trading. Heres how They Did. Barrons.com
02:49PM	CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19 Benzinga
01:57AM	Arcellx Announces Pricing of Initial Public Offering GlobeNewswire

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
New Enterprise Associates 15,	10% Owner	Jun 21	Buy	16.00	312,500	5,000,000	6,745,262	Jun 23 05:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience